Drug news
Velcade withdrawn from combination treatment of Follicular Lymphoma
Millennium Pharma, the subsidiary of Takeda specialising in oncology, will withdraw its supplemental new drug application to the FDA seeking a new use of Velcade (bortezomib) in combination with Rituxan (rituximab) from Genentech/Biogen Idec as a treatment for patients with relapsed follicular lymphoma.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.